Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Kush M. Parmar
AddedMar 31, 2024
UpdatedMay 31, 2026
Kush M. Parmar

Kush M. Parmar

Board Member, Entrada Therapeutics

CrunchbaseLinkedIn

Kush M. Parmar's Career

Entrada Therapeutics
Entrada Therapeutics

Boston, MA, US

Board Member· Board
Grace Science
Grace Science

San Francisco, CA, US

Board Member· Board
Ensoma
Ensoma

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Kush M. Parmar's Career

Entrada Therapeutics
Entrada Therapeutics
Public$201.6M1302016Boston, MA, US
Board Member· Board

Leadership at Entrada Therapeutics

Ziqing (Leo) QianZiqing (Leo) QianCo-Founder
Mary ThistleMary ThistleBoard Member
Dipal DoshiDipal DoshiBoard Member
Peter S. KimPeter S. KimBoard Member
Dehua PeiDehua PeiCo-Founder
Leo QianLeo QianCo-Founder
Grace Science
Grace Science
Seed$7M352017San Francisco, CA, US
Board Member· Board

Leadership at Grace Science

Matt WilseyMatt WilseyCEO
Kristen WilseyKristen WilseyFounder

Similar to Grace Science

Grit BioGrit BioNew York City, NY, USCancer Treatmentsest. 2017Grit BioNew York City, NY, US · est. 2017

Grit Bio: NY-based innovator of safer cancer treatments, specializing in pharyngeal carcinoma since 2017.

Angel · $256k6
GRAILGRAILMenlo Park, CA, USCancer Detectionest. 2016GRAILMenlo Park, CA, US · est. 2016

GRAIL, Inc., a Menlo Park-based biotech firm, specializes in early cancer detection using science and technology.

Public · $2B823
GliknikGliknikBaltimore, MD, USBiopharmaceuticals, Cancer Therapiesest. 2007GliknikBaltimore, MD, US · est. 2007

US-based Gliknik, Inc. develops therapies for cancer and immune disorders, producing drugs that enhance immune responses and kill tumor cells.

Series C · $70.1M75
Grannus TherapeuticsGrannus TherapeuticsIndianapolis, IN, USCancer Treatmentest. 2020Grannus TherapeuticsIndianapolis, IN, US · est. 2020

Grannus Therapeutics: An Indianapolis-based biotech firm specializing in cancer treatment since 2020.

Pre-Seed · $1.8M2
Ensoma
Ensoma
Series B$205M1262019Boston, MA, US
Board Member· Board

Leadership at Ensoma

Kouki HarasakiKouki HarasakiBoard Member
Hans-Peter KiemHans-Peter KiemCo-Founder
Emile NuwaysirEmile NuwaysirBoard Member
Paula SoteropoulosPaula SoteropoulosBoard Member
Andre LieberAndre LieberCo-Founder
Albert SeymourAlbert SeymourBoard Member

Kush M. Parmar's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Kush M. Parmar

Andy SchwabAndy SchwabBoard Member · National Venture Capital AssociationRob KornblumRob KornblumBoard Member · CircleInMarcus MurphyMarcus MurphyBoard Member · LinkedInNaimish PatelNaimish PatelBoard Member · UMA EnterprisesRekha HemrajaniRekha HemrajaniBoard Member · BioAge LabsPeter BaerPeter BaerCo-Founder · Twigmore